• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用正电子发射断层扫描术测量新型抗精神病候选药物卡利拉嗪(RGH-188)在猴脑中对多巴胺 D₂ 和 D₃ 以及 5-羟色胺 5-HT₁A 受体的占有率。

Occupancy of dopamine D₂ and D₃ and serotonin 5-HT₁A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography.

机构信息

Department of Clinical Neuroscience, Psychiatry Section, Karolinska Institutet, Stockholm 171 76, Sweden.

出版信息

Psychopharmacology (Berl). 2011 Dec;218(3):579-87. doi: 10.1007/s00213-011-2343-z. Epub 2011 May 28.

DOI:10.1007/s00213-011-2343-z
PMID:21625907
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3210913/
Abstract

RATIONALE

Cariprazine is a novel antipsychotic drug candidate that exhibits high selectivity and affinity to dopamine D(3) and D(2) receptors and moderate affinity to serotonin 5-HT(1A) receptors. Targeting receptors other than D(2) may provide a therapeutic benefit for both positive and negative symptoms associated with schizophrenia. Positron emission tomography (PET) can be used as a tool in drug development to assess the in vivo distribution and pharmacological properties of a drug.

OBJECTIVES

The objective of this study was to determine dopamine D(2)/D(3) and serotonin 5-HT(1A) receptor occupancy in monkey brain after the administration of cariprazine.

METHODS

We examined three monkeys using the following PET radioligands: [(11)C]MNPA (an agonist at D(2) and D(3) receptors), [(11)C]raclopride (an antagonist at D(2) and D(3) receptors), and [(11)C]WAY-100635 (an antagonist at 5-HT(1A) receptors). During each experimental day, the first PET measurement was a baseline study, the second after a low dose of cariprazine, and the third after the administration of a high dose.

RESULTS

We found that cariprazine occupied D(2)/D(3) receptors in a dose-dependent and saturable manner, with the lowest dose occupying ~5% of receptors and the highest dose showing more than 90% occupancy. 5-HT(1A) receptor occupancy was considerably lower compared with D(2)/D(3) occupancy at the same doses, with a maximal value of ~30% for the raphe nuclei.

CONCLUSIONS

We conclude that cariprazine binds preferentially to dopamine D(2)/D(3) rather than to serotonin 5-HT(1A) receptors in monkey brain. These findings can be used to guide the selection of cariprazine dosing in humans.

摘要

背景

卡利拉嗪是一种新型抗精神病候选药物,对多巴胺 D(3) 和 D(2) 受体具有高选择性和亲和力,对 5-羟色胺 5-HT(1A) 受体具有中等亲和力。针对除 D(2) 以外的受体可能为精神分裂症的阳性和阴性症状提供治疗益处。正电子发射断层扫描 (PET) 可作为药物开发中的一种工具,用于评估药物的体内分布和药理学特性。

目的

本研究的目的是确定卡利拉嗪给药后猴脑中多巴胺 D(2)/D(3) 和 5-羟色胺 5-HT(1A) 受体占有率。

方法

我们使用以下 PET 放射性配体检查了三只猴子:[(11)C]MNPA(D(2) 和 D(3) 受体激动剂)、[(11)C]raclopride(D(2) 和 D(3) 受体拮抗剂)和 [(11)C]WAY-100635(5-HT(1A) 受体拮抗剂)。在每个实验日,第一次 PET 测量为基线研究,第二次为低剂量卡利拉嗪给药后,第三次为高剂量给药后。

结果

我们发现卡利拉嗪以剂量依赖性和饱和方式占据 D(2)/D(3) 受体,最低剂量占据约 5%的受体,最高剂量显示超过 90%的占有率。与同一剂量的 D(2)/D(3) 占有率相比,5-HT(1A) 受体占有率明显较低,在中缝核的最大值约为 30%。

结论

我们得出结论,卡利拉嗪在猴脑中优先结合多巴胺 D(2)/D(3) 受体,而不是 5-羟色胺 5-HT(1A) 受体。这些发现可用于指导卡利拉嗪在人类中的剂量选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e42/3210913/8b705e7b5f33/nihms318242f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e42/3210913/1cbf7fe6877b/nihms318242f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e42/3210913/2afdf9822c69/nihms318242f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e42/3210913/47888803fe43/nihms318242f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e42/3210913/8b705e7b5f33/nihms318242f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e42/3210913/1cbf7fe6877b/nihms318242f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e42/3210913/2afdf9822c69/nihms318242f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e42/3210913/47888803fe43/nihms318242f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e42/3210913/8b705e7b5f33/nihms318242f4.jpg

相似文献

1
Occupancy of dopamine D₂ and D₃ and serotonin 5-HT₁A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography.使用正电子发射断层扫描术测量新型抗精神病候选药物卡利拉嗪(RGH-188)在猴脑中对多巴胺 D₂ 和 D₃ 以及 5-羟色胺 5-HT₁A 受体的占有率。
Psychopharmacology (Berl). 2011 Dec;218(3):579-87. doi: 10.1007/s00213-011-2343-z. Epub 2011 May 28.
2
Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO.在精神分裂症患者中,使用D3/D2受体配体[(11)C]-(+)-PHNO的PET研究显示,卡立普唑对多巴胺D3受体的结合优于D2受体。
Psychopharmacology (Berl). 2016 Oct;233(19-20):3503-12. doi: 10.1007/s00213-016-4382-y. Epub 2016 Aug 15.
3
Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.卡利拉嗪(RGH-188),一种多巴胺 D3 受体优先结合的、D3/D2 多巴胺受体拮抗剂-部分激动剂抗精神病候选药物:体外和神经化学特征。
J Pharmacol Exp Ther. 2010 Apr;333(1):328-40. doi: 10.1124/jpet.109.160432. Epub 2010 Jan 21.
4
Brain uptake and distribution of the dopamine D3 /D2 receptor partial agonist [11 C]cariprazine: an in vivo positron emission tomography study in nonhuman primates.脑内多巴胺 D3/D2 受体部分激动剂 [11C]卡利拉嗪摄取与分布:非人类灵长类动物体内正电子发射断层扫描研究。
Synapse. 2013 May;67(5):258-64. doi: 10.1002/syn.21631. Epub 2013 Feb 8.
5
Evaluation of dopamine D₂/D₃ and serotonin 5-HT₂A receptor occupancy for a novel antipsychotic, lurasidone, in conscious common marmosets using small-animal positron emission tomography.采用小动物正电子发射断层扫描技术评估新型抗精神病药鲁拉西酮在清醒食蟹猴体内对多巴胺 D₂/D₃ 和 5-羟色胺 5-HT₂A 受体的占有率。
Psychopharmacology (Berl). 2013 Jan;225(2):329-39. doi: 10.1007/s00213-012-2815-9. Epub 2012 Aug 7.
6
Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.阿立哌唑对精神分裂症患者D(2)、5-HT(2)和5-HT(1A)受体占有率的差异效应:一项三重示踪正电子发射断层扫描研究
Am J Psychiatry. 2007 Sep;164(9):1411-7. doi: 10.1176/appi.ajp.2007.06091479.
7
Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine.卡立普嗪主要代谢产物的临床前药效学和药代动力学特征
Drug Des Devel Ther. 2019 Sep 16;13:3229-3248. doi: 10.2147/DDDT.S188760. eCollection 2019.
8
Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone).齐拉西酮的纹状体和纹状体外D2/D3受体结合特性:一项使用[18F]法立哌德和[11C]雷氯必利的正电子发射断层扫描研究(齐拉西酮的D2/D3受体占有率)
J Clin Psychopharmacol. 2008 Dec;28(6):608-17. doi: 10.1097/JCP.0b013e31818ba2f6.
9
A positron emission tomography occupancy study of brexpiprazole at dopamine D and D and serotonin 5-HT and 5-HT receptors, and serotonin reuptake transporters in subjects with schizophrenia.一项针对精神分裂症患者的苯丁哌嗪在多巴胺 D 和 D、血清素 5-HT 和 5-HT 受体以及血清素再摄取转运体上占有率的正电子发射断层扫描研究。
Neuropsychopharmacology. 2020 Apr;45(5):786-792. doi: 10.1038/s41386-019-0590-6. Epub 2019 Dec 17.
10
Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia.新型抗精神病药布南色林对纹状体和纹状体外多巴胺 D2 受体占有率的影响:精神分裂症患者中[11C]raclopride 和 [11C]FLB 457 的 PET 研究。
J Clin Psychopharmacol. 2013 Apr;33(2):162-9. doi: 10.1097/JCP.0b013e3182825bce.

引用本文的文献

1
Third-Generation Antipsychotics: The Quest for the Key to Neurotrophism.第三代抗精神病药物:探寻神经营养作用的关键
Life (Basel). 2025 Mar 1;15(3):391. doi: 10.3390/life15030391.
2
Negative Symptoms of Schizophrenia: New Prospects of Cariprazine Treatment.精神分裂症的阴性症状:卡利拉嗪治疗的新前景
Consort Psychiatr. 2020 Dec 4;1(2):43-51. doi: 10.17650/2712-7672-2020-1-2-43-51.
3
A review on the pharmacology of cariprazine and its role in the treatment of negative symptoms of schizophrenia.卡立普嗪的药理学及其在治疗精神分裂症阴性症状中的作用综述。

本文引用的文献

1
Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy.用 [11C]-(+)-PHNO 对人类多巴胺受体进行成像:D3 信号与解剖结构的剖析。
Neuroimage. 2011 Jan 1;54(1):264-77. doi: 10.1016/j.neuroimage.2010.06.044. Epub 2010 Jun 30.
2
Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist.正电子发射断层扫描(PET)、[11C]PHNO 和选择性 D3 受体拮抗剂在人脑中成像多巴胺 D3 受体。
Biol Psychiatry. 2010 Aug 15;68(4):392-9. doi: 10.1016/j.biopsych.2010.04.038.
3
Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
Front Psychiatry. 2024 Apr 22;15:1385925. doi: 10.3389/fpsyt.2024.1385925. eCollection 2024.
4
Effects of buprenorphine, methadone, and cariprazine on economic choice between remifentanil and food in squirrel monkeys.丁丙诺啡、美沙酮和卡立普多对松鼠猴在瑞芬太尼和食物之间经济选择的影响。
Addict Neurosci. 2023 Mar;5. doi: 10.1016/j.addicn.2023.100065. Epub 2023 Jan 18.
5
Molecular Imaging of Dopamine Partial Agonists in Humans: Implications for Clinical Practice.多巴胺部分激动剂在人体中的分子成像:对临床实践的启示。
Front Psychiatry. 2022 Apr 6;13:832209. doi: 10.3389/fpsyt.2022.832209. eCollection 2022.
6
Real-Life Clinical Experience With Cariprazine: A Systematic Review of Case Studies.卡立普嗪的真实临床经验:病例研究的系统评价
Front Psychiatry. 2022 Mar 17;13:827744. doi: 10.3389/fpsyt.2022.827744. eCollection 2022.
7
New Antipsychotic Medications in the Last Decade.过去十年中的新型抗精神病药物。
Curr Psychiatry Rep. 2021 Nov 29;23(12):87. doi: 10.1007/s11920-021-01298-w.
8
Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine.卡立普嗪主要代谢产物的临床前药效学和药代动力学特征
Drug Des Devel Ther. 2019 Sep 16;13:3229-3248. doi: 10.2147/DDDT.S188760. eCollection 2019.
9
Hunting for the high-affinity state of G-protein-coupled receptors with agonist tracers: Theoretical and practical considerations for positron emission tomography imaging.用激动剂示踪剂寻找高亲和力状态的 G 蛋白偶联受体:正电子发射断层成像的理论和实际考虑因素。
Med Res Rev. 2019 May;39(3):1014-1052. doi: 10.1002/med.21552. Epub 2018 Nov 18.
10
Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy.卡立普嗪用于成人精神分裂症的急性和维持治疗:基于证据的综述及在治疗中的地位
Neuropsychiatr Dis Treat. 2018 Oct 5;14:2563-2577. doi: 10.2147/NDT.S159704. eCollection 2018.
卡利拉嗪(RGH-188),一种多巴胺 D3 受体优先结合的、D3/D2 多巴胺受体拮抗剂-部分激动剂抗精神病候选药物:体外和神经化学特征。
J Pharmacol Exp Ther. 2010 Apr;333(1):328-40. doi: 10.1124/jpet.109.160432. Epub 2010 Jan 21.
4
In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: Studies in non-human primates and transgenic mice.(+)-PHNO区域多巴胺-D3受体结合潜能的体内定量研究:在非人灵长类动物和转基因小鼠中的研究。
Synapse. 2009 Sep;63(9):782-93. doi: 10.1002/syn.20658.
5
The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO.抗精神病药物对D2和D3受体高亲和力状态的影响:一项使用[11C]-(+)-PHNO的正电子发射断层扫描研究
Arch Gen Psychiatry. 2009 Jun;66(6):606-15. doi: 10.1001/archgenpsychiatry.2009.43.
6
Pharmacological characterization of 2-methoxy-N-propylnorapomorphine's interactions with D2 and D3 dopamine receptors.2-甲氧基-N-丙基去甲阿扑吗啡与D2和D3多巴胺受体相互作用的药理学特征
Synapse. 2009 Jun;63(6):462-75. doi: 10.1002/syn.20626.
7
Dopamine D(2/3) receptor occupancy of apomorphine in the nonhuman primate brain--a comparative PET study with [11C]raclopride and [11C]MNPA.非人灵长类动物脑中阿扑吗啡对多巴胺D(2/3)受体的占有率——一项使用[11C]雷氯必利和[11C]MNPA的比较性PET研究
Synapse. 2009 May;63(5):378-89. doi: 10.1002/syn.20615.
8
The role of imaging in proof of concept for CNS drug discovery and development.成像在中枢神经系统药物发现与开发概念验证中的作用。
Neuropsychopharmacology. 2009 Jan;34(1):187-203. doi: 10.1038/npp.2008.166. Epub 2008 Oct 8.
9
The role of molecular imaging in drug discovery and development.分子成像在药物研发中的作用。
Clin Pharmacol Ther. 2008 Feb;83(2):349-53. doi: 10.1038/sj.clpt.6100467. Epub 2008 Jan 2.
10
Using positron emission tomography to facilitate CNS drug development.利用正电子发射断层扫描技术促进中枢神经系统药物研发。
Trends Pharmacol Sci. 2006 Jun;27(6):310-6. doi: 10.1016/j.tips.2006.04.004. Epub 2006 May 6.